BENİGN PROSTAT HİPERPLAZİSİ ÜZERİNDE ETKİLİ FİTOTERAPÖTİKLER

Ufuk Çalışkan; Gökşen Dilşat Durbilmez; Gökmen Memiş

doi:10.33483/jfpau.459798

Derleme

BENİGN PROSTAT HİPERPLAZİSİ ÜZERİNDE ETKİLİ FİTOTERAPÖTİKLER

Yıl 2019, Cilt: 43 Sayı: 2, 173 - 196, 01.06.2019

Ufuk Çalışkan Gökşen Dilşat Durbilmez Gökmen Memiş

https://doi.org/10.33483/jfpau.459798

Öz

Amaç: İyi huylu prostat büyümesi (Benign Prostat Hiperplazisi=BPH), elli yaş
üstü erkeklerin ortalama üçte birinde görülen hem idrar depolama, boşaltma ve
boşaltma sonrası semptomlara yol açan, hem de olguların yaşam kalitesini bozan
bir durumdur. BPH’ye bağlı alt üriner sistem hastalıklarının tedavisinde
fitoterapötikler uzun zamandan beri klinik uygulamalarda yer almaktadır. Bu
çalışmanın amacı BPH tedavisinde en sık kullanılan fitoterapötikler olan
Cucurbita pepo, Epilobium sp., Hypoxis rooperi, Lycopersicon esculentum Mill.,
Pinus pinaster Aiton, Pygeum africanum, Roystonea regia (Kunth) O.F. Cook,
Secale cereale, Serenoa repens, Urtica dioica’nın etkinlikleri ve yapılan
önemli klinik çalışmaları derlemektir.

Sonuç ve Tartışma: Kanıta
dayalı tıp zemininde BPH’ye yönelik alt üriner sistem hastalıklarının
tedavisinde fitoterapötiklerin birçok semptomda düzelme sağladığı söylenmekle
birlikte çalışmalar daha fazla plasebo kontrollü, çift-kör randomize
çalışmalara ihtiyaç duyulduğunu göstermektedir.

Anahtar Kelimeler

BPH, fitoterapötikler, prostat rahatsızlıkları

Kaynakça

1.Çam, K. (2008). Benign prostat hiperplazisinde fitoterapi. Üroonkoloji Bülteni, 3, 33-37.
2. Görür, S., Baydinç, Y.C. (2010). (Benign prostat hiperplazisinde fitoterapi) phytotherapy in benign prostatic hyperplasia, Türk Üroloji Seminerleri, 1, 9-13.
3. Pagano, E., Laudato, M., Griffo, M., & Capasso, R. (2014). Phytotherapy of benign prostatic hyperplasia. A minireview. Phytotherapy research, 28(7), 949-955. 4. Frydenberg, M. (2010), Prostate Enlargement (BPH). Andrology Australia, 1-2.
4. Frydenberg, M. (2010), Prostate Enlargement (BPH). Andrology Australia, 1-2.
5. Sandhu, J.S., Te, A.E. (2004). Benign Prostatic Hyperplasia (BPH), Encyclopedia of Endocrine Diseases, 1, 341–344.
6. Kaynar, M., & Göktaş, S. (2014). Benign Prostat Hiperplazisinde Fitoterapi. Bulletin of Urooncology, 13, 236-240.
7. Sezik, E. (2002). Prostat (erkelerin korkulu riyası). Eczacı. Sayı (2). Sayfa 26-28.
8.Erbin, A., Berberoğlu, A. Y., Sarılar, Ö., Binbay, M., & Müslümanoğlu, A. Y. (2012). Benign Prostat Hiperplazisi Tedavisinde Uygulanan Minimal İnvaziv Yöntemler. Bulletin of Haseki, 50, 76-80.
9. Özden, E., & Şahin, A. (2005). Benign Prostat Hiperplazisinde Lazer Tedavisi. Turkiye Klinikleri Journal of Surgical Medical Sciences, 1(1), 82-86.10. Bach, D. (2000). Placebokontrollierte Langzeittherapiestudie mit Kürbissamenextrakt bei BPH-bedingten Miktionsbeschwerden. Der Urologe B, 40(5), 437-443.
10. Bach, D. (2000). Placebokontrollierte Langzeittherapiestudie mit Kürbissamenextrakt bei BPH-bedingten Miktionsbeschwerden. Der Urologe B, 40(5), 437-443.
11. Vahlensieck, W., Theurer, C., Pfitzer, E., Patz, B., Banik, N., & Engelmann, U. (2015). Effects of pumpkin seed in men with lower urinary tract symptoms due to benign prostatic hyperplasia in the one-year, randomized, placebo-controlled GRANU study. Urologia internationalis, 94(3), 286-295.
12. Tsai, Y. S., Tong, Y. C., Cheng, J. T., Lee, C. H., Yang, F. S., & Lee, H. Y. (2006). Pumpkin seed oil and phytosterol-F can block testosterone/prazosin-induced prostate growth in rats. Urologia internationalis, 77(3), 269-274.
13. PDR for Herbal Medicines, third ed. Thomson PDR at Montvale, USA, 2004
14. Berges, R. R., Windeler, J., Trampisch, H. J., Senge, T. H., & β-Sitosterol Study Group. (1995). Randomised, placebo-controlled, double-blind clinical trial of β-sitosterol in patients with benign prostatic hyperplasia. The Lancet, 345(8964), 1529-1532.
15. Klippel, K. F., Hiltl, D. M., Schipp, B., & German BPH‐Phyto study group‡. (1997). A multicentric, placebo‐controlled, double‐blind clinical trial of β‐sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. British journal of urology, 80(3), 427-432.
16. Wilt, T., Ishani, A., Mac, R. D., Rutks, I., & Stark, G. (2002). Pygeum africanum for benign prostatic hyperplasia. The Cochrane database of systematic reviews, (1), CD001044-CD001044.
17. Chatelain, C., Autet, W., & Brackman, F. (1999). Comparison of once and twice daily dosage forms of Pygeum africanum extract in patients with benign prostatic hyperplasia: a randomized, double-blind study, with long-term open label extension1. Urology, 54(3), 473-478.
18. Edgar, A. D., Levin, R., Constantinou, C. E., & Denis, L. (2007). A critical review of the pharmacology of the plant extract of Pygeum africanum in the treatment of LUTS. Neurourology and urodynamics, 26(4), 458-463.
19. Wilt, T. J., Macdonald, R., Ishani, A., Rutks, I., & Stark, G. (2011). WITHDRAWN: Cernilton for benign prostatic hyperplasia. The Cochrane database of systematic reviews, (5), CD001042-CD001042.
20. Kamijo, T., Sato, S., & Kitamura, T. (2001). Effect of cernitin pollen‐extract on experimental nonbacterial prostatitis in rats. The Prostate, 49(2), 122-131.
21. Wagenlehner, F. M., Schneider, H., Ludwig, M., Schnitker, J., Brähler, E., & Weidner, W. (2009). A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis–chronic pelvic pain syndrome: a multicentre, randomised, prospective, double-blind, placebo-controlled phase 3 study. European urology, 56(3), 544-551.
22. Buck, A. C. (2004). Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action. The Journal of urology, 172(5), 1792-1799.
23. Tacklind, J., MacDonald, R., Rutks, I., & Wilt, T. J. (2009). Serenoa repens for benign prostatic hyperplasia. Cochrane database of systematic reviews (Online), (2), CD001423.
24. Bent, S., Kane, C., Shinohara, K., Neuhaus, J., Hudes, E. S., Goldberg, H., & Avins, A. L. (2006). Saw palmetto for benign prostatic hyperplasia. New England Journal of Medicine, 354(6), 557-566.
25. Safarinejad, M. R. (2005). Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study. Journal of herbal pharmacotherapy, 5(4), 1-11.26. Chrubasik, J. E., Roufogalis, B. D., Wagner, H., & Chrubasik, S. (2007). A comprehensive review on the stinging nettle effect and efficacy profiles. Part II: urticae radix. Phytomedicine, 14(7-8), 568-579.
26. Chrubasik, J. E., Roufogalis, B. D., Wagner, H., & Chrubasik, S. (2007). A comprehensive review on the stinging nettle effect and efficacy profiles. Part II: urticae radix. Phytomedicine, 14(7-8), 568-579.
27. Erdem, S., & Kadıoğlu, A. Benign prostat hiperplazisinde fitoterapi (Güncel Makale Özeti). Androloji Bülteni, 18(64), 13-19.
28. Đorđević, I., Milutinović, M., Kostić, M., Đorđević, B., Dimitrijević, M., Stošić, N., ... & Kitić, D. (2016). Phytotherapeutic approach to benign prostatic hyperplasia treatment by pumpkin seed (Cucurbita pepo L., Cucurbitaceae). Acta Medica Medianae, 55(3), 76-84.
29. Allkanjari, O., & Vitalone, A. (2015). What do we know about phytotherapy of benign prostatic hyperplasia?. Life sciences, 126, 42-56.
30. MaiTra, T. (2013). Phytotherapy for Lower Urinary Tract Symptoms due to Benign Hyperplasia of Prostate. Indian Journal of Clinical Practice, 24(1).
31. Wilt, T. J., Ishani, A., Rutks, I., & MacDonald, R. (2000). Phytotherapy for benign prostatic hyperplasia. Public health nutrition, 3(4a), 459-472.
32. Gažová, A., Valášková, S., Žufková, V., Castejon, A. M., & Kyselovič, J. (2018). Clinical study of effectiveness and safety of CELcomplex® containing Cucurbita Pepo Seed extract and Flax and Casuarina on stress urinary incontinence in women. Journal of Traditional and Complementary Medicine.
33. Vitalone, A., & Allkanjari, O. (2018). Epilobium spp: Pharmacology and Phytochemistry. Phytotherapy Research.
34. Monschein, M., Jaindl, K., Buzimkić, S., & Bucar, F. (2015). Content of phenolic compounds in wild populations of Epilobium angustifolium growing at different altitudes. Pharmaceutical biology, 53(11), 1576-1582.
35. Berges, R. R., Kassen, A., & Senge, T. (2000). Treatment of symptomatic benign prostatic hyperplasia with β‐sitosterol: an 18‐month follow‐up. BJU international, 85(7), 842-846.
36. Lowe, F.C. (2001). Phytotherapy in the management of benign prostatic hyperplasia. Urology, 58(6-1), 71-6-7.
37. Wilt, T. J., MacDonald, R., & Ishani, A. (1999). -sitosterol for the treatment of benign prostatic hyperplasia: a systematic review. BJU international, 83, 976-983.
38. Madersbacher, S., Ponholzer, A., Berger, I., & Marszalek, M. (2007). Medical management of BPH: role of plant extracts. eau-ebu update series, 5(5), 197-205.
39. Edinger, M. S., & Koff, W. J. (2006). Effect of the consumption of tomato paste on plasma prostate-specific antigen levels in patients with benign prostate hyperplasia. Brazilian journal of medical and biological research, 39(8), 1115-1119.
40. Gann, P. H., Deaton, R. J., Rueter, E. E., Van Breemen, R. B., Nonn, L., Macias, V., ... & Ananthanarayanan, V. (2015). A phase II randomized trial of lycopene-rich tomato extract among men with high-grade prostatic intraepithelial neoplasia. Nutrition and cancer, 67(7), 1104-1112.
41. Zou, Y., Sun, Q., Li, J., Yang, C., Yang, J., & Zhang, L. (2014). Effects of E/Z isomers of lycopene on experimental prostatic hyperplasia in mice. Fitoterapia, 99, 211-217.
42. Yagi, H., Sato, R., Nishio, K., Arai, G., Soh, S., & Okada, H. (2017). Effects of a supplement combining Pycnogenol® and l-arginine aspartate on lower urinary dysfunction compared with saw palmetto extract. Journal of traditional and complementary medicine, 7(1), 117-120
43. Lawson, R. K. (1997). Role of growth factors in benign prostatic hyperplasia. European urology, 32, 22-27.
44. Dedhia, R. C., & McVary, K. T. (2008). Phytotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia. The Journal of urology, 179(6), 2119-2125.45. Ooi, S. L., & Pak, S. C. (2017). Serenoa repens for lower urinary tract symptoms/benign prostatic hyperplasia: current evidence and its clinical implications in naturopathic medicine. The Journal of Alternative and Complementary Medicine, 23(8), 599-606.
45. Ooi, S. L., & Pak, S. C. (2017). Serenoa repens for lower urinary tract symptoms/benign prostatic hyperplasia: current evidence and its clinical implications in naturopathic medicine. The Journal of Alternative and Complementary Medicine, 23(8), 599-606.
46. Wilt, T., Ishani, A., & MacDonald, R. (2002). Serenoa repens for benign prostatic hyperplasia. Cochrane Database of Systematic Reviews, (3).
47. Morgia, G., Micali, A., Rinaldi, M., Irrera, N., Marini, H., Puzzolo, D., ... & Ieni, A. (2017). Survivin and NAIP in human benign prostatic hyperplasia: protective role of the association of Serenoa repens, lycopene and selenium from the randomized clinical study. International journal of molecular sciences, 18(3), 680.
48. Paterniti, I., Campolo, M., Cordaro, M., Siracusa, R., Filippone, A., Esposito, E., & Cuzzocrea, S. (2018). Effects of different natural extracts in an experimental model of benign prostatic hyperplasia (BPH). Inflammation Research, 67(7), 617-626.
49. Vela‐Navarrete, R., Alcaraz, A., Rodríguez‐Antolín, A., Miñana López, B., Fernández‐Gómez, J. M., Angulo, J. C., ... & Molero García, J. M. (2018). Efficacy and safety of a hexanic extract of Serenoa repens (Permixon®) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta‐analysis of randomised controlled trials and observational studies. BJU international.
50. Nahata, A., & Dixit, V. K. (2012). Ameliorative effects of stinging nettle (Urtica dioica) on testosterone‐induced prostatic hyperplasia in rats. Andrologia, 44, 396-409.
51. Moradi, H. R., Majd, N. E., Esmaeilzadeh, S., & Tabatabaei, S. R. F. (2015). The histological and histometrical effects of Urtica dioica extract on rat’s prostate hyperplasia. In Veterinary Research Forum (Vol. 6, No. 1, p. 23). Faculty of Veterinary Medicine, Urmia University, Urmia, Iran.
52. Chrubasik, J. E., Roufogalis, B. D., Wagner, H., & Chrubasik, S. (2007). A comprehensive review on the stinging nettle effect and efficacy profiles. Part II: urticae radix. Phytomedicine, 14(7-8), Popa, G., Hägele-Kaddour, H., & Walther, C. (2005). Efficacy of a combined Sabal-urtica preparation in the symptomatic treatment of benign prostatic hyperplasia. Results of a placebo-controlled double-blind study. MMW Fortschritte der Medizin, 147, 103-108.568-579.
53. Popa, G., Hägele-Kaddour, H., & Walther, C. (2005). Efficacy of a combined Sabal-urtica preparation in the symptomatic treatment of benign prostatic hyperplasia. Results of a placebo-controlled double-blind study. MMW Fortschritte der Medizin, 147, 103-108.
54. Moradi, H. R., Majd, N. E., Esmaeilzadeh, S., & Tabatabaei, S. R. F. (2015). The histological and histometrical effects of Urtica dioica extract on rat’s prostate hyperplasia. In Veterinary Research Forum (Vol. 6, No. 1, p. 23). Faculty of Veterinary Medicine, Urmia University, Urmia, Iran.
55. Wu, X., Gu, Y., & Li, L. (2017). The anti-hyperplasia, anti-oxidative and anti-inflammatory properties of Qing Ye Dan and swertiamarin in testosterone-induced benign prostatic hyperplasia in rats. Toxicology letters, 265, 9-16.
56. Ryu, J. M., Jang, G. Y., Park, D., Woo, K. S., Kim, T. M., Jeong, H. S., & Kim, D. J. (2018). Effect of sorghum ethyl-acetate extract on benign prostatic hyperplasia induced by testosterone in Sprague–Dawley rats. Bioscience, biotechnology, and biochemistry, 1-8.
57. Zhou, J., Lei, Y., Chen, J., & Zhou, X. (2018). Potential ameliorative effects of epigallocatechin 3 gallate against testosterone-induced benign prostatic hyperplasia and fibrosis in rats. International immunopharmacology, 64, 162-169.
58. Rx media pharma, 2018

EFFECTS OF PHYTOTERAPEUTICS ON BENIGN PROSTATE HYPERPLASIA

Yıl 2019, Cilt: 43 Sayı: 2, 173 - 196, 01.06.2019

Ufuk Çalışkan Gökşen Dilşat Durbilmez Gökmen Memiş

https://doi.org/10.33483/jfpau.459798

Öz

Objective: Benign prostatic hyperplasia (BPH) is a condition that causes symptoms
during urinary storage, discharge and after discharge, which are seen in an
average one third of men over the age of fifty, as well as disrupts the quality
of life. Phytotherapeutics have long been involved in clinical practice in the treatment
of lower urinary tract symptoms associated with BPH. The goal of this study is
to review pharmacological and clinical studies on Cucurbita pepo, Epilobium
sp., Hypoxis rooperi, Lycopersicon esculentum Mill., Pinus pinaster Aiton,
Pygeum africanum, Roystonea regia (Kunth) O.F. Cook, Secale cereale, Serenoa
repens, Urtica dioica, which are the most frequently used plant species in BPH
treatment.

Result and Discussion: It is argued that
phytotherapeutics improve symptoms in the treatment of lower urinary tract for
BPH, on the other hand most of the studies shows that more placebo-controlled,
double-blind randomization studies involving large patient numbers were needed.

Anahtar Kelimeler

BPH, phytotherapeutic, prostatic disease

Kaynakça

1.Çam, K. (2008). Benign prostat hiperplazisinde fitoterapi. Üroonkoloji Bülteni, 3, 33-37.
2. Görür, S., Baydinç, Y.C. (2010). (Benign prostat hiperplazisinde fitoterapi) phytotherapy in benign prostatic hyperplasia, Türk Üroloji Seminerleri, 1, 9-13.
3. Pagano, E., Laudato, M., Griffo, M., & Capasso, R. (2014). Phytotherapy of benign prostatic hyperplasia. A minireview. Phytotherapy research, 28(7), 949-955. 4. Frydenberg, M. (2010), Prostate Enlargement (BPH). Andrology Australia, 1-2.
4. Frydenberg, M. (2010), Prostate Enlargement (BPH). Andrology Australia, 1-2.
5. Sandhu, J.S., Te, A.E. (2004). Benign Prostatic Hyperplasia (BPH), Encyclopedia of Endocrine Diseases, 1, 341–344.
6. Kaynar, M., & Göktaş, S. (2014). Benign Prostat Hiperplazisinde Fitoterapi. Bulletin of Urooncology, 13, 236-240.
7. Sezik, E. (2002). Prostat (erkelerin korkulu riyası). Eczacı. Sayı (2). Sayfa 26-28.
8.Erbin, A., Berberoğlu, A. Y., Sarılar, Ö., Binbay, M., & Müslümanoğlu, A. Y. (2012). Benign Prostat Hiperplazisi Tedavisinde Uygulanan Minimal İnvaziv Yöntemler. Bulletin of Haseki, 50, 76-80.
9. Özden, E., & Şahin, A. (2005). Benign Prostat Hiperplazisinde Lazer Tedavisi. Turkiye Klinikleri Journal of Surgical Medical Sciences, 1(1), 82-86.10. Bach, D. (2000). Placebokontrollierte Langzeittherapiestudie mit Kürbissamenextrakt bei BPH-bedingten Miktionsbeschwerden. Der Urologe B, 40(5), 437-443.
10. Bach, D. (2000). Placebokontrollierte Langzeittherapiestudie mit Kürbissamenextrakt bei BPH-bedingten Miktionsbeschwerden. Der Urologe B, 40(5), 437-443.
11. Vahlensieck, W., Theurer, C., Pfitzer, E., Patz, B., Banik, N., & Engelmann, U. (2015). Effects of pumpkin seed in men with lower urinary tract symptoms due to benign prostatic hyperplasia in the one-year, randomized, placebo-controlled GRANU study. Urologia internationalis, 94(3), 286-295.
12. Tsai, Y. S., Tong, Y. C., Cheng, J. T., Lee, C. H., Yang, F. S., & Lee, H. Y. (2006). Pumpkin seed oil and phytosterol-F can block testosterone/prazosin-induced prostate growth in rats. Urologia internationalis, 77(3), 269-274.
13. PDR for Herbal Medicines, third ed. Thomson PDR at Montvale, USA, 2004
14. Berges, R. R., Windeler, J., Trampisch, H. J., Senge, T. H., & β-Sitosterol Study Group. (1995). Randomised, placebo-controlled, double-blind clinical trial of β-sitosterol in patients with benign prostatic hyperplasia. The Lancet, 345(8964), 1529-1532.
15. Klippel, K. F., Hiltl, D. M., Schipp, B., & German BPH‐Phyto study group‡. (1997). A multicentric, placebo‐controlled, double‐blind clinical trial of β‐sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. British journal of urology, 80(3), 427-432.
16. Wilt, T., Ishani, A., Mac, R. D., Rutks, I., & Stark, G. (2002). Pygeum africanum for benign prostatic hyperplasia. The Cochrane database of systematic reviews, (1), CD001044-CD001044.
17. Chatelain, C., Autet, W., & Brackman, F. (1999). Comparison of once and twice daily dosage forms of Pygeum africanum extract in patients with benign prostatic hyperplasia: a randomized, double-blind study, with long-term open label extension1. Urology, 54(3), 473-478.
18. Edgar, A. D., Levin, R., Constantinou, C. E., & Denis, L. (2007). A critical review of the pharmacology of the plant extract of Pygeum africanum in the treatment of LUTS. Neurourology and urodynamics, 26(4), 458-463.
19. Wilt, T. J., Macdonald, R., Ishani, A., Rutks, I., & Stark, G. (2011). WITHDRAWN: Cernilton for benign prostatic hyperplasia. The Cochrane database of systematic reviews, (5), CD001042-CD001042.
20. Kamijo, T., Sato, S., & Kitamura, T. (2001). Effect of cernitin pollen‐extract on experimental nonbacterial prostatitis in rats. The Prostate, 49(2), 122-131.
21. Wagenlehner, F. M., Schneider, H., Ludwig, M., Schnitker, J., Brähler, E., & Weidner, W. (2009). A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis–chronic pelvic pain syndrome: a multicentre, randomised, prospective, double-blind, placebo-controlled phase 3 study. European urology, 56(3), 544-551.
22. Buck, A. C. (2004). Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action. The Journal of urology, 172(5), 1792-1799.
23. Tacklind, J., MacDonald, R., Rutks, I., & Wilt, T. J. (2009). Serenoa repens for benign prostatic hyperplasia. Cochrane database of systematic reviews (Online), (2), CD001423.
24. Bent, S., Kane, C., Shinohara, K., Neuhaus, J., Hudes, E. S., Goldberg, H., & Avins, A. L. (2006). Saw palmetto for benign prostatic hyperplasia. New England Journal of Medicine, 354(6), 557-566.
25. Safarinejad, M. R. (2005). Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study. Journal of herbal pharmacotherapy, 5(4), 1-11.26. Chrubasik, J. E., Roufogalis, B. D., Wagner, H., & Chrubasik, S. (2007). A comprehensive review on the stinging nettle effect and efficacy profiles. Part II: urticae radix. Phytomedicine, 14(7-8), 568-579.
26. Chrubasik, J. E., Roufogalis, B. D., Wagner, H., & Chrubasik, S. (2007). A comprehensive review on the stinging nettle effect and efficacy profiles. Part II: urticae radix. Phytomedicine, 14(7-8), 568-579.
27. Erdem, S., & Kadıoğlu, A. Benign prostat hiperplazisinde fitoterapi (Güncel Makale Özeti). Androloji Bülteni, 18(64), 13-19.
28. Đorđević, I., Milutinović, M., Kostić, M., Đorđević, B., Dimitrijević, M., Stošić, N., ... & Kitić, D. (2016). Phytotherapeutic approach to benign prostatic hyperplasia treatment by pumpkin seed (Cucurbita pepo L., Cucurbitaceae). Acta Medica Medianae, 55(3), 76-84.
29. Allkanjari, O., & Vitalone, A. (2015). What do we know about phytotherapy of benign prostatic hyperplasia?. Life sciences, 126, 42-56.
30. MaiTra, T. (2013). Phytotherapy for Lower Urinary Tract Symptoms due to Benign Hyperplasia of Prostate. Indian Journal of Clinical Practice, 24(1).
31. Wilt, T. J., Ishani, A., Rutks, I., & MacDonald, R. (2000). Phytotherapy for benign prostatic hyperplasia. Public health nutrition, 3(4a), 459-472.
32. Gažová, A., Valášková, S., Žufková, V., Castejon, A. M., & Kyselovič, J. (2018). Clinical study of effectiveness and safety of CELcomplex® containing Cucurbita Pepo Seed extract and Flax and Casuarina on stress urinary incontinence in women. Journal of Traditional and Complementary Medicine.
33. Vitalone, A., & Allkanjari, O. (2018). Epilobium spp: Pharmacology and Phytochemistry. Phytotherapy Research.
34. Monschein, M., Jaindl, K., Buzimkić, S., & Bucar, F. (2015). Content of phenolic compounds in wild populations of Epilobium angustifolium growing at different altitudes. Pharmaceutical biology, 53(11), 1576-1582.
35. Berges, R. R., Kassen, A., & Senge, T. (2000). Treatment of symptomatic benign prostatic hyperplasia with β‐sitosterol: an 18‐month follow‐up. BJU international, 85(7), 842-846.
36. Lowe, F.C. (2001). Phytotherapy in the management of benign prostatic hyperplasia. Urology, 58(6-1), 71-6-7.
37. Wilt, T. J., MacDonald, R., & Ishani, A. (1999). -sitosterol for the treatment of benign prostatic hyperplasia: a systematic review. BJU international, 83, 976-983.
38. Madersbacher, S., Ponholzer, A., Berger, I., & Marszalek, M. (2007). Medical management of BPH: role of plant extracts. eau-ebu update series, 5(5), 197-205.
39. Edinger, M. S., & Koff, W. J. (2006). Effect of the consumption of tomato paste on plasma prostate-specific antigen levels in patients with benign prostate hyperplasia. Brazilian journal of medical and biological research, 39(8), 1115-1119.
40. Gann, P. H., Deaton, R. J., Rueter, E. E., Van Breemen, R. B., Nonn, L., Macias, V., ... & Ananthanarayanan, V. (2015). A phase II randomized trial of lycopene-rich tomato extract among men with high-grade prostatic intraepithelial neoplasia. Nutrition and cancer, 67(7), 1104-1112.
41. Zou, Y., Sun, Q., Li, J., Yang, C., Yang, J., & Zhang, L. (2014). Effects of E/Z isomers of lycopene on experimental prostatic hyperplasia in mice. Fitoterapia, 99, 211-217.
42. Yagi, H., Sato, R., Nishio, K., Arai, G., Soh, S., & Okada, H. (2017). Effects of a supplement combining Pycnogenol® and l-arginine aspartate on lower urinary dysfunction compared with saw palmetto extract. Journal of traditional and complementary medicine, 7(1), 117-120
43. Lawson, R. K. (1997). Role of growth factors in benign prostatic hyperplasia. European urology, 32, 22-27.
44. Dedhia, R. C., & McVary, K. T. (2008). Phytotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia. The Journal of urology, 179(6), 2119-2125.45. Ooi, S. L., & Pak, S. C. (2017). Serenoa repens for lower urinary tract symptoms/benign prostatic hyperplasia: current evidence and its clinical implications in naturopathic medicine. The Journal of Alternative and Complementary Medicine, 23(8), 599-606.
45. Ooi, S. L., & Pak, S. C. (2017). Serenoa repens for lower urinary tract symptoms/benign prostatic hyperplasia: current evidence and its clinical implications in naturopathic medicine. The Journal of Alternative and Complementary Medicine, 23(8), 599-606.
46. Wilt, T., Ishani, A., & MacDonald, R. (2002). Serenoa repens for benign prostatic hyperplasia. Cochrane Database of Systematic Reviews, (3).
47. Morgia, G., Micali, A., Rinaldi, M., Irrera, N., Marini, H., Puzzolo, D., ... & Ieni, A. (2017). Survivin and NAIP in human benign prostatic hyperplasia: protective role of the association of Serenoa repens, lycopene and selenium from the randomized clinical study. International journal of molecular sciences, 18(3), 680.
48. Paterniti, I., Campolo, M., Cordaro, M., Siracusa, R., Filippone, A., Esposito, E., & Cuzzocrea, S. (2018). Effects of different natural extracts in an experimental model of benign prostatic hyperplasia (BPH). Inflammation Research, 67(7), 617-626.
49. Vela‐Navarrete, R., Alcaraz, A., Rodríguez‐Antolín, A., Miñana López, B., Fernández‐Gómez, J. M., Angulo, J. C., ... & Molero García, J. M. (2018). Efficacy and safety of a hexanic extract of Serenoa repens (Permixon®) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta‐analysis of randomised controlled trials and observational studies. BJU international.
50. Nahata, A., & Dixit, V. K. (2012). Ameliorative effects of stinging nettle (Urtica dioica) on testosterone‐induced prostatic hyperplasia in rats. Andrologia, 44, 396-409.
51. Moradi, H. R., Majd, N. E., Esmaeilzadeh, S., & Tabatabaei, S. R. F. (2015). The histological and histometrical effects of Urtica dioica extract on rat’s prostate hyperplasia. In Veterinary Research Forum (Vol. 6, No. 1, p. 23). Faculty of Veterinary Medicine, Urmia University, Urmia, Iran.
52. Chrubasik, J. E., Roufogalis, B. D., Wagner, H., & Chrubasik, S. (2007). A comprehensive review on the stinging nettle effect and efficacy profiles. Part II: urticae radix. Phytomedicine, 14(7-8), Popa, G., Hägele-Kaddour, H., & Walther, C. (2005). Efficacy of a combined Sabal-urtica preparation in the symptomatic treatment of benign prostatic hyperplasia. Results of a placebo-controlled double-blind study. MMW Fortschritte der Medizin, 147, 103-108.568-579.
53. Popa, G., Hägele-Kaddour, H., & Walther, C. (2005). Efficacy of a combined Sabal-urtica preparation in the symptomatic treatment of benign prostatic hyperplasia. Results of a placebo-controlled double-blind study. MMW Fortschritte der Medizin, 147, 103-108.
54. Moradi, H. R., Majd, N. E., Esmaeilzadeh, S., & Tabatabaei, S. R. F. (2015). The histological and histometrical effects of Urtica dioica extract on rat’s prostate hyperplasia. In Veterinary Research Forum (Vol. 6, No. 1, p. 23). Faculty of Veterinary Medicine, Urmia University, Urmia, Iran.
55. Wu, X., Gu, Y., & Li, L. (2017). The anti-hyperplasia, anti-oxidative and anti-inflammatory properties of Qing Ye Dan and swertiamarin in testosterone-induced benign prostatic hyperplasia in rats. Toxicology letters, 265, 9-16.
56. Ryu, J. M., Jang, G. Y., Park, D., Woo, K. S., Kim, T. M., Jeong, H. S., & Kim, D. J. (2018). Effect of sorghum ethyl-acetate extract on benign prostatic hyperplasia induced by testosterone in Sprague–Dawley rats. Bioscience, biotechnology, and biochemistry, 1-8.
57. Zhou, J., Lei, Y., Chen, J., & Zhou, X. (2018). Potential ameliorative effects of epigallocatechin 3 gallate against testosterone-induced benign prostatic hyperplasia and fibrosis in rats. International immunopharmacology, 64, 162-169.
58. Rx media pharma, 2018

Toplam 58 adet kaynakça vardır.

Ayrıntılar

Birincil Dil	Türkçe
Konular	Eczacılık ve İlaç Bilimleri
Bölüm	Derleme
Yazarlar	Ufuk Çalışkan Gökşen Dilşat Durbilmez Bu kişi benim Gökmen Memiş Bu kişi benim
Yayımlanma Tarihi	1 Haziran 2019
Gönderilme Tarihi	13 Eylül 2018
Kabul Tarihi	11 Şubat 2019
Yayımlandığı Sayı	Yıl 2019 Cilt: 43 Sayı: 2

Kaynak Göster

APA	Çalışkan, U., Durbilmez, G. D., & Memiş, G. (2019). BENİGN PROSTAT HİPERPLAZİSİ ÜZERİNDE ETKİLİ FİTOTERAPÖTİKLER. Journal of Faculty of Pharmacy of Ankara University, 43(2), 173-196. https://doi.org/10.33483/jfpau.459798
AMA	Çalışkan U, Durbilmez GD, Memiş G. BENİGN PROSTAT HİPERPLAZİSİ ÜZERİNDE ETKİLİ FİTOTERAPÖTİKLER. Ankara Ecz. Fak. Derg. Haziran 2019;43(2):173-196. doi:10.33483/jfpau.459798
Chicago	Çalışkan, Ufuk, Gökşen Dilşat Durbilmez, ve Gökmen Memiş. “BENİGN PROSTAT HİPERPLAZİSİ ÜZERİNDE ETKİLİ FİTOTERAPÖTİKLER”. Journal of Faculty of Pharmacy of Ankara University 43, sy. 2 (Haziran 2019): 173-96. https://doi.org/10.33483/jfpau.459798.
EndNote	Çalışkan U, Durbilmez GD, Memiş G (01 Haziran 2019) BENİGN PROSTAT HİPERPLAZİSİ ÜZERİNDE ETKİLİ FİTOTERAPÖTİKLER. Journal of Faculty of Pharmacy of Ankara University 43 2 173–196.
IEEE	U. Çalışkan, G. D. Durbilmez, ve G. Memiş, “BENİGN PROSTAT HİPERPLAZİSİ ÜZERİNDE ETKİLİ FİTOTERAPÖTİKLER”, Ankara Ecz. Fak. Derg., c. 43, sy. 2, ss. 173–196, 2019, doi: 10.33483/jfpau.459798.
ISNAD	Çalışkan, Ufuk vd. “BENİGN PROSTAT HİPERPLAZİSİ ÜZERİNDE ETKİLİ FİTOTERAPÖTİKLER”. Journal of Faculty of Pharmacy of Ankara University 43/2 (Haziran 2019), 173-196. https://doi.org/10.33483/jfpau.459798.
JAMA	Çalışkan U, Durbilmez GD, Memiş G. BENİGN PROSTAT HİPERPLAZİSİ ÜZERİNDE ETKİLİ FİTOTERAPÖTİKLER. Ankara Ecz. Fak. Derg. 2019;43:173–196.
MLA	Çalışkan, Ufuk vd. “BENİGN PROSTAT HİPERPLAZİSİ ÜZERİNDE ETKİLİ FİTOTERAPÖTİKLER”. Journal of Faculty of Pharmacy of Ankara University, c. 43, sy. 2, 2019, ss. 173-96, doi:10.33483/jfpau.459798.
Vancouver	Çalışkan U, Durbilmez GD, Memiş G. BENİGN PROSTAT HİPERPLAZİSİ ÜZERİNDE ETKİLİ FİTOTERAPÖTİKLER. Ankara Ecz. Fak. Derg. 2019;43(2):173-96.

Kapak Resmi İndir

Makale Dosyaları

Tam Metin

Kapsam ve Amaç

Ankara Üniversitesi Eczacılık Fakültesi Dergisi, açık erişim, hakemli bir dergi olup Türkçe veya İngilizce olarak farmasötik bilimler alanındaki önemli gelişmeleri içeren orijinal araştırmalar, derlemeler ve kısa bildiriler için uluslararası bir yayım ortamıdır. Bilimsel toplantılarda sunulan bildiriler supleman özel sayısı olarak dergide yayımlanabilir. Ayrıca, tüm farmasötik alandaki gelecek ve önceki ulusal ve uluslararası bilimsel toplantılar ile sosyal aktiviteleri içerir.